JP7358245B2 - 障害の処置のための細菌 - Google Patents

障害の処置のための細菌 Download PDF

Info

Publication number
JP7358245B2
JP7358245B2 JP2019571258A JP2019571258A JP7358245B2 JP 7358245 B2 JP7358245 B2 JP 7358245B2 JP 2019571258 A JP2019571258 A JP 2019571258A JP 2019571258 A JP2019571258 A JP 2019571258A JP 7358245 B2 JP7358245 B2 JP 7358245B2
Authority
JP
Japan
Prior art keywords
ecolin
phage
genes encoding
genes
operably linked
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
JP2019571258A
Other languages
English (en)
Japanese (ja)
Other versions
JP2020525012A5 (https=
JP2020525012A (ja
Inventor
ファルブ ディーン
ビー フィッシャー アダム
エム イザベラ ビンセント
ダブリュー コツラ ジョナサン
ロプコヴィッツ デイビッド
エフ ミラー ポール
ミレー イブ
エリザベス ロウ サラ
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Synlogic Inc
Original Assignee
Synlogic Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Synlogic Inc filed Critical Synlogic Inc
Publication of JP2020525012A publication Critical patent/JP2020525012A/ja
Publication of JP2020525012A5 publication Critical patent/JP2020525012A5/ja
Priority to JP2023093143A priority Critical patent/JP7639056B2/ja
Application granted granted Critical
Publication of JP7358245B2 publication Critical patent/JP7358245B2/ja
Priority to JP2025025000A priority patent/JP2025087727A/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Images

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N1/00—Microorganisms; Compositions thereof; Processes of propagating, maintaining or preserving microorganisms or compositions thereof; Processes of preparing or isolating a composition containing a microorganism; Culture media therefor
    • C12N1/20—Bacteria; Culture media therefor
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/195—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria
    • C07K14/24—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria from Enterobacteriaceae (F), e.g. Citrobacter, Serratia, Proteus, Providencia, Morganella, Yersinia
    • C07K14/245—Escherichia (G)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/66—Microorganisms or materials therefrom
    • A61K35/74—Bacteria
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/66—Microorganisms or materials therefrom
    • A61K35/74—Bacteria
    • A61K35/741—Probiotics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
    • C12N9/0004—Oxidoreductases (1.)
    • C12N9/0012—Oxidoreductases (1.) acting on nitrogen containing compounds as donors (1.4, 1.5, 1.6, 1.7)
    • C12N9/0014—Oxidoreductases (1.) acting on nitrogen containing compounds as donors (1.4, 1.5, 1.6, 1.7) acting on the CH-NH2 group of donors (1.4)
    • C12N9/0022—Oxidoreductases (1.) acting on nitrogen containing compounds as donors (1.4, 1.5, 1.6, 1.7) acting on the CH-NH2 group of donors (1.4) with oxygen as acceptor (1.4.3)
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
    • C12N9/88—Lyases (4.)
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2510/00—Genetically modified cells
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2795/00—Bacteriophages
    • C12N2795/00011—Details
    • C12N2795/00021—Viruses as such, e.g. new isolates, mutants or their genomic sequences
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2800/00—Nucleic acids vectors
    • C12N2800/20—Pseudochromosomes, minichrosomosomes
    • C12N2800/202—Pseudochromosomes, minichrosomosomes of bacteriophage origin
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/527—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving lyase
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Genetics & Genomics (AREA)
  • Engineering & Computer Science (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Zoology (AREA)
  • Wood Science & Technology (AREA)
  • Microbiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Molecular Biology (AREA)
  • Biotechnology (AREA)
  • Biochemistry (AREA)
  • General Engineering & Computer Science (AREA)
  • Biomedical Technology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Mycology (AREA)
  • Biophysics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Virology (AREA)
  • Nutrition Science (AREA)
  • Physiology (AREA)
  • Physics & Mathematics (AREA)
  • Plant Pathology (AREA)
  • Analytical Chemistry (AREA)
  • Immunology (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
JP2019571258A 2017-06-21 2018-06-21 障害の処置のための細菌 Active JP7358245B2 (ja)

Priority Applications (2)

Application Number Priority Date Filing Date Title
JP2023093143A JP7639056B2 (ja) 2017-06-21 2023-06-06 障害の処置のための細菌
JP2025025000A JP2025087727A (ja) 2017-06-21 2025-02-19 障害の処置のための細菌

Applications Claiming Priority (13)

Application Number Priority Date Filing Date Title
US201762523202P 2017-06-21 2017-06-21
US201762523225P 2017-06-21 2017-06-21
US62/523,202 2017-06-21
US62/523,225 2017-06-21
US201762552829P 2017-08-31 2017-08-31
US201762552785P 2017-08-31 2017-08-31
US62/552,829 2017-08-31
US62/552,785 2017-08-31
US201862614213P 2018-01-05 2018-01-05
US62/614,213 2018-01-05
US201862624299P 2018-01-31 2018-01-31
US62/624,299 2018-01-31
PCT/US2018/038840 WO2018237198A1 (en) 2017-06-21 2018-06-21 BACTERIA FOR THE TREATMENT OF DISORDERS

Related Child Applications (1)

Application Number Title Priority Date Filing Date
JP2023093143A Division JP7639056B2 (ja) 2017-06-21 2023-06-06 障害の処置のための細菌

Publications (3)

Publication Number Publication Date
JP2020525012A JP2020525012A (ja) 2020-08-27
JP2020525012A5 JP2020525012A5 (https=) 2021-07-26
JP7358245B2 true JP7358245B2 (ja) 2023-10-10

Family

ID=62909623

Family Applications (3)

Application Number Title Priority Date Filing Date
JP2019571258A Active JP7358245B2 (ja) 2017-06-21 2018-06-21 障害の処置のための細菌
JP2023093143A Active JP7639056B2 (ja) 2017-06-21 2023-06-06 障害の処置のための細菌
JP2025025000A Pending JP2025087727A (ja) 2017-06-21 2025-02-19 障害の処置のための細菌

Family Applications After (2)

Application Number Title Priority Date Filing Date
JP2023093143A Active JP7639056B2 (ja) 2017-06-21 2023-06-06 障害の処置のための細菌
JP2025025000A Pending JP2025087727A (ja) 2017-06-21 2025-02-19 障害の処置のための細菌

Country Status (8)

Country Link
US (2) US11879123B2 (https=)
EP (1) EP3642221A1 (https=)
JP (3) JP7358245B2 (https=)
CN (1) CN111655841A (https=)
AU (2) AU2018290278B2 (https=)
CA (1) CA3066085A1 (https=)
IL (1) IL271085B2 (https=)
WO (1) WO2018237198A1 (https=)

Families Citing this family (28)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ES2881384T3 (es) 2015-05-13 2021-11-29 Synlogic Operating Co Inc Bacterias manipuladas para reducir la hiperfenilalaninemia
CN111655841A (zh) 2017-06-21 2020-09-11 同生运营公司 用于治疗紊乱的细菌
US11560543B2 (en) 2017-09-14 2023-01-24 University Of Massachusetts Genetically engineered microorganisms and methods of use
CN108048342B (zh) * 2017-10-26 2021-06-04 中国农业大学 一种耐压益生菌及其食品和制备方法
US11541105B2 (en) 2018-06-01 2023-01-03 The Research Foundation For The State University Of New York Compositions and methods for disrupting biofilm formation and maintenance
KR20220003030A (ko) 2019-04-29 2022-01-07 신로직 오퍼레이팅 컴퍼니, 인코포레이티드 살아 있는 세포 계수 기술에 의한 유전적으로 조작된 미생물의 계수
EP3962506A4 (en) 2019-05-03 2022-07-13 University Of Massachusetts GMO MICROORGANISMS AND METHODS OF USE
WO2020257395A1 (en) * 2019-06-21 2020-12-24 Inscripta, Inc. Genome-wide rationally-designed mutations leading to enhanced lysine production in e. coli
CN110592057B (zh) * 2019-09-27 2022-01-28 昆明理工大学 嵌合裂解酶ILTphg和编码此酶的多核苷酸
WO2021127648A1 (en) * 2019-12-19 2021-06-24 Auburn University Microbial ester production
BR112022013867A2 (pt) * 2020-01-14 2022-09-13 Synlogic Operating Co Inc Bactérias manipuladas para tratar distúrbios nos quais o oxalato é prejudicial
CN111235169A (zh) * 2020-02-03 2020-06-05 昆明理工大学 一种GTP环化水解酶I基因folE及应用
US12571020B2 (en) 2020-02-24 2026-03-10 University Of Massachusetts Genetically engineered microorganisms that overexpress microcin-mge and methods of purification and use
US20230105474A1 (en) * 2020-02-25 2023-04-06 Synlogic Operating Company, Inc. Recombinant bacteria engineered to treat diseases associated with uric acid and methods of use thereof
BR112022018571A2 (pt) * 2020-03-20 2022-11-01 Synlogic Operating Co Inc Microrganismos manipulados para reduzir a hiperfenilalaninemia
US20220031771A1 (en) * 2020-07-31 2022-02-03 Iowa State University Research Foundation, Inc. Microencapsulated and chromosome integrated compositions for l-dopa microbiome therapy
CN111876400B (zh) * 2020-08-06 2022-05-24 昆明理工大学 一种常温裂解酶Sly和编码此酶的多核苷酸
EP4256039A2 (en) 2020-12-02 2023-10-11 Synlogic Operating Company, Inc. Engineered microorganisms
CN116847860A (zh) * 2020-12-31 2023-10-03 同生运营公司 经工程化以减轻高苯丙氨酸血症的微生物
CN112662607A (zh) * 2021-01-07 2021-04-16 上海陶宇晟生物技术有限责任公司 具备表面展示苯丙氨酸解氨酶的工程益生菌
WO2022204406A1 (en) * 2021-03-24 2022-09-29 Synlogic Operating Company, Inc. Bacteria engineered to treat disorders in which oxalate is detrimental
CN113789276B (zh) * 2021-09-15 2023-05-12 千宠堂(福建)生物科技有限公司 一株产β-烟酰胺单核苷酸的植物乳杆菌及其应用
WO2023044479A1 (en) 2021-09-17 2023-03-23 Synlogic Operating Company, Inc. Methods for reducing hyperphenylalaninemia
CN116555063B (zh) * 2022-01-27 2025-08-08 中国海洋大学 动物双歧杆菌f1-7在降解苯丙氨酸中的应用
CN116179452A (zh) * 2022-07-11 2023-05-30 山东第一医科大学(山东省医学科学院) 一种用于治疗精氨酸酶缺乏症的工程益生菌及其构建方法和应用
EP4605522A1 (en) 2022-10-17 2025-08-27 Synlogic Operating Company, Inc. Recombinant bacteria expressing phenylalanine ammonia lyase, phenylalanine transporter and l- aminoacid deaminase for reducing hyperphenylalaninemia
WO2025199288A1 (en) * 2024-03-20 2025-09-25 The Texas A&M University System Programmable payload overproduction and delivery
CN119875979A (zh) * 2025-01-20 2025-04-25 浙江工业大学 一种基于I型CRISPRi筛选系统构建的高产β-丙氨酸工程菌及方法

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2016183531A1 (en) 2015-05-13 2016-11-17 Synlogic, Inc. Bacteria engineered to reduce hyperphenylalaninemia

Family Cites Families (50)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4946778A (en) 1987-09-21 1990-08-07 Genex Corporation Single polypeptide chain binding molecules
GB9107305D0 (en) 1991-04-08 1991-05-22 Unilever Plc Probiotic
CN1154845A (zh) 1996-09-09 1997-07-23 首都医学院附属北京红十字朝阳医院 能表达活性苯丙氨酸脱氨酶的基因工程菌口服制剂
US5989463A (en) 1997-09-24 1999-11-23 Alkermes Controlled Therapeutics, Inc. Methods for fabricating polymer-based controlled release devices
US6203797B1 (en) 1998-01-06 2001-03-20 Stephen C. Perry Dietary supplement and method for use as a probiotic, for alleviating the symptons associated with irritable bowel syndrome
EP1034787A1 (en) 1999-03-11 2000-09-13 Société des Produits Nestlé S.A. Lactobacillus strains preventing diarrhea caused by pathogenic bacteria
JP4682454B2 (ja) 2000-06-28 2011-05-11 味の素株式会社 新規変異型ｎ−アセチルグルタミン酸合成酵素及びｌ−アルギニンの製造法
AUPQ899700A0 (en) 2000-07-25 2000-08-17 Borody, Thomas Julius Probiotic recolonisation therapy
DK1383897T3 (da) 2001-05-03 2006-10-30 Vlaams Interuniv Inst Biotech Selv-containing Lactococcus-stamme
US7314974B2 (en) 2002-02-21 2008-01-01 Monsanto Technology, Llc Expression of microbial proteins in plants for production of plants with improved properties
US7731976B2 (en) 2003-08-29 2010-06-08 Cobb And Company, Llp Treatment of irritable bowel syndrome using probiotic composition
JP4452914B2 (ja) 2003-09-08 2010-04-21 味の素株式会社 新規トランスポータタンパク質
EP2080769A3 (en) 2004-07-02 2010-12-01 Metanomics GmbH Process for the production of fine chemicals
WO2006034373A2 (en) 2004-09-17 2006-03-30 Biomarin Pharmaceutical Inc. Variants and chemically-modified variants of phenylalanine ammonia-lyase
ZA200704766B (en) 2004-11-30 2008-09-25 Aeras Global Tb Vaccine Found Bacterial packaging strains useful for generation and production of recombinant double-stranded RNA nucleocapsids and uses thereof
GB0501540D0 (en) 2005-01-25 2005-03-02 Univ Leeds Controlled production and delivery of biologically active agents by gut bacteria
EP2886658A1 (en) 2005-03-10 2015-06-24 BASF Enzymes LLC Lyase enzymes, nucleic acids encoding them and methods for making and using them
WO2008118176A2 (en) 2006-06-02 2008-10-02 Verenium Corporation Lase enzymes, nucleic acids encoding them and methods for making and using them
TW200819540A (en) 2006-07-11 2008-05-01 Genelux Corp Methods and compositions for detection of microorganisms and cells and treatment of diseases and disorders
US9084434B2 (en) 2006-09-27 2015-07-21 Little Calumet Holdings Llc Probiotic oral dosage forms
US20100297249A1 (en) 2007-07-05 2010-11-25 North-West University Enhancement of the efficacy of therapeutic proteins
CN101586111B (zh) 2008-05-22 2012-03-07 北京三元基因工程有限公司 一种活性乳酸乳球菌制品的制备方法
EP3181682B1 (en) 2008-09-29 2021-04-21 Intrexon Actobiotics NV Reduced colonization of microbes at the mucosa
MX2012001508A (es) 2009-08-04 2013-05-30 Evogene Ltd Polinucleotidos y polipeptidos aislados, y metodos para utilizarlos para mejorar la tolerancia al estres abiotico, rendimiento, tasa de crecimiento, vigor, biomasa, contenido de aceite y/o eficacia en el uso de nitrogeno de las plantas.
WO2011080505A2 (en) 2009-12-28 2011-07-07 Bigdna Ltd Method of growing phage for commercial use
BR112012022054A2 (pt) 2010-03-02 2015-09-15 Functional Technologies Corp microorganismo transformado, método de redução de asparagina durante o preparo ou processamento de alimento, médtodo de redução de acrilamidia em um produto alimentício, e, produto alimentício
US8129170B1 (en) 2010-12-06 2012-03-06 E.I. Du Pont De Nemours And Company Recombinant bacteria having the ability to metabolize sucrose
EP2655624B1 (en) 2010-12-23 2017-11-29 Biogen MA Inc. Linker peptides and polypeptides comprising same
US9017961B2 (en) 2012-03-05 2015-04-28 E.I. Du Pont De Nemours And Company Recombinant bacteria comprising novel sucrose transporters
FR2990699B1 (fr) 2012-05-21 2016-02-05 Agronomique Inst Nat Rech Cassettes d'expression procaryotes regulees par le stress
US20150337336A1 (en) 2012-06-22 2015-11-26 Phytogene, Inc. Enzymes and methods for styrene synthesis
AU2013295621A1 (en) 2012-07-27 2015-03-12 University Of North Texas Genetically modified probiotic for the treatment of phenylketonuria (PKU) disease
WO2014066945A1 (en) 2012-11-01 2014-05-08 The Sydney Children's Hospital Network (Randwick & Westmead) Genetically-modified probiotic for treatment of phenylketonuria
CN105144204B (zh) 2012-12-13 2018-02-27 麻省理工学院 基于重组酶的逻辑与存储系统
JP6283040B2 (ja) 2013-03-07 2018-02-21 ザ ジェネラル ホスピタル コーポレイション 細菌によるポリペプチド送達のための組成物および方法
NZ713396A (en) 2013-04-18 2020-06-26 Codexis Inc Engineered phenylalanine ammonia lyase polypeptides
SG11201704543XA (en) 2014-12-05 2017-07-28 Synlogic Inc Bacteria engineered to treat diseases associated with hyperammonemia
WO2016183532A1 (en) 2015-05-13 2016-11-17 Synlogic, Inc. Bacteria engineered to treat a disease or disorder
US9688967B2 (en) 2014-12-05 2017-06-27 Synlogic, Inc. Bacteria engineered to treat diseases associated with hyperammonemia
JP7095993B2 (ja) 2015-03-02 2022-07-05 シンロジック オペレーティング カンパニー インコーポレイテッド 消化管炎症低下および／または消化管粘膜バリア強化の利益を享受する疾患処置のために操作された細菌
JP6799010B2 (ja) 2015-05-28 2020-12-09 エヴォルヴァ エスアー．Ｅｖｏｌｖａ Ｓａ． フェニルプロパノイドおよびフェニルプロパノイド誘導体の生合成
AU2016276973B2 (en) 2015-06-10 2022-09-01 Synlogic Operating Company, Inc. Bacteria engineered to treat disorders involving the catabolism of a branched chain amino acid
WO2016210373A2 (en) 2015-06-24 2016-12-29 Synlogic, Inc. Recombinant bacteria engineered for biosafety, pharmaceutical compositions, and methods of use thereof
US20170216370A1 (en) 2015-07-31 2017-08-03 Synlogic, Inc. Bacteria engineered to treat disorders involving propionate catabolism
ES2925049T3 (es) 2015-11-16 2022-10-13 Synlogic Operating Co Inc Bacterias manipuladas para reducir la hiperfenilalaninemia
EP3402498A1 (en) 2016-01-11 2018-11-21 Synlogic, Inc. Microorganisms programmed to produce immune modulators and anti-cancer therapeutics in tumor cells
WO2017216704A1 (en) 2016-06-13 2017-12-21 Benson Hill Biosystems, Inc. Increasing plant growth and yield by using a phenylalanine ammonia lyase sequence
CN111655841A (zh) 2017-06-21 2020-09-11 同生运营公司 用于治疗紊乱的细菌
JP2021531749A (ja) 2018-07-12 2021-11-25 コデクシス， インコーポレイテッド 操作されたフェニルアラニンアンモニアリアーゼポリペプチド
BR112022018571A2 (pt) 2020-03-20 2022-11-01 Synlogic Operating Co Inc Microrganismos manipulados para reduzir a hiperfenilalaninemia

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2016183531A1 (en) 2015-05-13 2016-11-17 Synlogic, Inc. Bacteria engineered to reduce hyperphenylalaninemia

Non-Patent Citations (2)

* Cited by examiner, † Cited by third party
Title
Appl.Microbiol.Biotechnol.,2016,100(20),p.8693-8699
J.Biotechnol.,2005,117(2),p.147-161

Also Published As

Publication number Publication date
IL271085B1 (en) 2024-03-01
JP7639056B2 (ja) 2025-03-04
AU2018290278B2 (en) 2022-12-15
AU2018290278A1 (en) 2019-12-19
US12545886B2 (en) 2026-02-10
WO2018237198A1 (en) 2018-12-27
CA3066085A1 (en) 2018-12-27
CN111655841A (zh) 2020-09-11
AU2023201271A1 (en) 2023-04-06
JP2020525012A (ja) 2020-08-27
JP2025087727A (ja) 2025-06-10
AU2023201271B2 (en) 2026-01-29
JP2023123506A (ja) 2023-09-05
EP3642221A1 (en) 2020-04-29
IL271085B2 (en) 2024-07-01
IL271085A (en) 2020-01-30
US20240368531A1 (en) 2024-11-07
US11879123B2 (en) 2024-01-23
US20200172857A1 (en) 2020-06-04

Similar Documents

Publication Publication Date Title
JP7639056B2 (ja) 障害の処置のための細菌
JP7592777B2 (ja) 高フェニルアラニン血症を低減させるように操作された細菌
US20230043588A1 (en) Bacteria engineered to treat diseases that benefit from reduced gut inflammation and/or tightened gut mucosal barrier
JP2020525012A5 (https=)
JP7494345B2 (ja) 高フェニルアラニン血症を低減させるように操作された細菌
US20240110192A1 (en) Bacteria engineered to treat diseases that benefit from reduced gut inflammation and/or tightened gut mucosal barrier
US10273489B2 (en) Bacteria engineered to treat diseases that benefit from reduced gut inflammation and/or tightened gut mucosal barrier
US11685925B2 (en) Bacteria engineered to treat diseases that benefit from reduced gut inflammation and/or tightened gut mucosal barrier
WO2016210373A2 (en) Recombinant bacteria engineered for biosafety, pharmaceutical compositions, and methods of use thereof
JP2018535678A5 (https=)
US20210161976A1 (en) Bacteria engineered to treat diseases that benefit from reduced gut inflammation and/or tightened gut mucosal barrier
CN115335066A (zh) 经工程化以治疗其中草酸盐有害的病症的细菌

Legal Events

Date Code Title Description
A524 Written submission of copy of amendment under article 19 pct

Free format text: JAPANESE INTERMEDIATE CODE: A524

Effective date: 20210217

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20210609

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20210609

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20220531

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20220812

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20221031

A02 Decision of refusal

Free format text: JAPANESE INTERMEDIATE CODE: A02

Effective date: 20230207

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20230606

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A821

Effective date: 20230607

A911 Transfer to examiner for re-examination before appeal (zenchi)

Free format text: JAPANESE INTERMEDIATE CODE: A911

Effective date: 20230626

TRDD Decision of grant or rejection written
A01 Written decision to grant a patent or to grant a registration (utility model)

Free format text: JAPANESE INTERMEDIATE CODE: A01

Effective date: 20230829

A61 First payment of annual fees (during grant procedure)

Free format text: JAPANESE INTERMEDIATE CODE: A61

Effective date: 20230927

R150 Certificate of patent or registration of utility model

Ref document number: 7358245

Country of ref document: JP

Free format text: JAPANESE INTERMEDIATE CODE: R150